(Total Views: 350)
Posted On: 06/25/2020 2:43:23 PM
Post# of 231
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Another Step in Advancement of Lead Drug Candidate for NSCLC
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that the United States Adopted Names (“USAN”) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex(TM) immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (“NSCLC”). “The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” Rodney Varner, chairman and CEO of Genprex, stated in the news release. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway. In the meantime, we’ve focused our branding efforts on our proprietary, non-viral nanoparticle delivery system with our recognized Oncoprex(TM) name. We believe this delivery system is a significant differentiator for GPX-001, as well as an important platform delivery system that could be used for additional drug candidates.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that the United States Adopted Names (“USAN”) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex(TM) immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (“NSCLC”). “The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” Rodney Varner, chairman and CEO of Genprex, stated in the news release. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway. In the meantime, we’ve focused our branding efforts on our proprietary, non-viral nanoparticle delivery system with our recognized Oncoprex(TM) name. We believe this delivery system is a significant differentiator for GPX-001, as well as an important platform delivery system that could be used for additional drug candidates.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
